CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy

Authors:
  • TKTakayuki Kobayashi
    Takayuki Kobayashi
  • JXJingyu Xiang
    Jingyu Xiang
  • YXYalin Xu
    Yalin Xu
  • ASAyesha N. Shajahan-Haq
    Ayesha N. Shajahan-Haq
  • MMMahta Mardani
    Mahta Mardani
  • SNSuleyman Noordeen
    Suleyman Noordeen
  • KOKaylee O’DOnnell
    Kaylee O’DOnnell
  • KKKristin A. Kwakwa
    Kristin A. Kwakwa
  • DGDennis Guan
    Dennis Guan
  • GFGregory C. Fox
    Gregory C. Fox
  • FFFrancesca Fontana
    Francesca Fontana

Abstract
No abstract available
Funding Information
  • Hope Center for Neurological Disorders, Washington University in St. Louis
  • U.S. Department of War (W81XWH-16-1-0286)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30-AR074992)
  • Cancer Prevention and Research Institute of Texas (F30CA254215)
  • Cancer Prevention and Research Institute of Texas (RR220013)
  • Cancer Prevention and Research Institute of Texas (R01CA248526)
  • Cancer Prevention and Research Institute of Texas (R01CA237263)
  • Musculoskeletal Research Center, Washington University in St. Louis
  • Washington University in St. Louis (NCI S10 OD02742)
  • Novartis
  • National Institutes of Health (U54CA199092)
  • National Cancer Institute (P01 CA100730)
  • National Cancer Institute (R01 CA216840)
  • School of Medicine, Washington University in St. Louis (T32CA009547)

This publication has 44 references indexed in Scilit: